Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 24, Issue 11, Pages -Publisher
MDPI
DOI: 10.3390/ijms24119683
Keywords
tau immunotherapy; tau cleavage; Amyloid Precursor Protein (APP); Amyloid beta peptide (A beta); Alzheimer's Disease (AD); endocytosis; bioenergetics; neuroprotection
Ask authors/readers for more resources
In addition to deficits in hippocampal-dependent episodic memory, Alzheimer's Disease (AD) is characterized by sensory impairment in visual cognition due to extensive neuropathology in the retina. A monoclonal antibody called 12A12 has been found to specifically neutralize the harmful tau fragments associated with AD without affecting the normal protein. When administered to a mouse model of AD, 12A12 successfully reduces the accumulation of these tau fragments in the brain and retina, improving the associated symptoms. This study also reveals that 12A12 downregulates the expression of proteins involved in the production of amyloid beta, leading to a decrease in its accumulation in both the hippocampus and retina.
Beyond deficits in hippocampal-dependent episodic memory, Alzheimer's Disease (AD) features sensory impairment in visual cognition consistent with extensive neuropathology in the retina. 12A12 is a monoclonal cleavage specific antibody (mAb) that in vivo selectively neutralizes the AD-relevant, harmful N-terminal 20-22 kDa tau fragment(s) (i.e., NH(2)htau) without affecting the full-length normal protein. When systemically injected into the Tg2576 mouse model overexpressing a mutant form of Amyloid Precursor Protein (APP), APPK670/671L linked to early onset familial AD, this conformation-specific tau mAb successfully reduces the NH(2)htau accumulating both in their brain and retina and, thus, markedly alleviates the phenotype-associated signs. By means of a combined biochemical and metabolic experimental approach, we report that 12A12mAb downregulates the steady state expression levels of APP and Beta-Secretase 1 (BACE-1) and, thus, limits the Amyloid beta (A beta) production both in the hippocampus and retina from this AD animal model. The local, antibody-mediated anti-amyloidogenic action is paralleled in vivo by coordinated modulation of the endocytic (BIN1, RIN3) and bioenergetic (glycolysis and L-Lactate) pathways. These findings indicate for the first time that similar molecular and metabolic retino-cerebral pathways are modulated in a coordinated fashion in response to 12A12mAb treatment to tackle the neurosensorial Afi accumulation in AD neurodegeneration.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available